Diabetes Drug Empagliflozin May Slow Kidney Disease Progression (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
The diabetes drug empagliflozin — a selective sodium-glucose cotransporter 2 inhibitor — may help slow progression of kidney disease in patients at high cardiovascular risk, according to a …
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | Primary Care | Urology & Nephrology